FrancophonIA/ELRC3.0 huggingface dataset:
English: --1 Live attenuated Muscovy duck parvovirus ≥ 2.6 log10 CCID50 * * Cell culture infectious dose 50%
Estonian: --1 Muskuspartide elus nõrgestatud parvovirus ≥ 2.6 log10 CCID50 * * rakukultuuri infitseeriv doos 50%
English: Packaging Content Package size
Estonian: Sisaldus Pakendi suurus
English: Suspension and diluent for suspension for injection
Estonian: Suspensioon ja lahusti süstesuspensiooni valmistamiseks
English: Strength Pharmaceutical form
Estonian: Nimetus Tugevus Ravimvorm Loomaliigid
English: Muscovy ducks
Estonian: Muskuspardid
English: EU (MA) Number
Estonian: EL number
English: Not applicable
Estonian: Keeluajad
English: 10 vials Not applicable
Estonian: Antigeen: viaal (klaass)
English: 1 vial
Estonian: Muskus
English: Withdrawal period
Estonian: Suspensioon ja
English: This summary was last updated in 12-2016.
Estonian: Kokkuvõtte viimane uuendus: 12-2016.
English: These side effects are generally mild or moderate.
Estonian: Need kõrvalnähud on üldiselt kerged või mõõdukad.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Relistor on 2 July 2008.
Estonian: Euroopa Komisjon andis Relistori müügiloa, mis kehtib kogu Euroopa Liidus, 2. juulil 2008.
English: The percentages of successful injections for the two groups were around 30% and 9%, respectively.
Estonian: Edukate süstete protsent kummaski rühmas oli ligikaudu 30% ja 9%.
English: The full EPAR for Relistor can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Relistori kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: What measures are being taken to ensure the safe and effective use of Relistor?
Estonian: Mis meetmed võetakse, et tagada Relistori ohutu ja efektiivne kasutamine?
English: These receptors are also found in the gut.
Estonian: Neid retseptoreid leidub ka seedetraktis.
English: Other information about Relistor
Estonian: Muu teave Relistori kohta
English: The Agency's Committee for Medicinal Products for Human Use decided that Relistor's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Relistori kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: What is Relistor and what is it used for?
Estonian: Mis on Relistor ja milleks seda kasutatakse?
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Relistor have been included in the summary of product characteristics and the package leaflet.
Estonian: Relistori ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: This is a summary of the European public assessment report (EPAR) for Relistor.
Estonian: See on ravimi Relistor Euroopa avaliku hindamisaruande kokkuvõte.
English: Relistor has also been compared with placebo in a third study involving 496 patients with constipation caused by opioids, but no advanced illness.
Estonian: Relistori võrreldi platseeboga ka kolmandas uuringus, milles osales 496 patsienti, kellel oli opioididest põhjustatud kõhukinnisus, kuid haigus ei olnud süvenenud.
English: The dose depends on the patient's body weight.
Estonian: Annus sõltub patsiendi kehamassist.
English: Relistor is not recommended for patients who have very severe kidney problems that require dialysis (a blood clearance technique).
Estonian: Relistori ei soovitata väga raskete neeruprobleemidega patsientidele, kes vajavad dialüüsi (teatud verepuhastustehnika).
English: The most common side effects with Relistor (seen in more than 1 patient in 10) are abdominal pain (stomach ache), nausea (feeling sick), diarrhoea and flatulence.
Estonian: Relistori kõige sagedamad kõrvalnähud (esinenud enam kui 1 patsiendil 10st) on kõhuvalu, iiveldus, kõhulahtisus ja kõhupuhitus.
English: Why is Relistor approved?
Estonian: Miks Relistor heaks kiideti?
English: In patients who are receiving palliative care (treatment of the symptoms of a serious disease that is not intended to lead to cure), Relistor is given as an injection under the skin, once every two days, in addition to the usual laxative medicines.
Estonian: Patsientidele, kes saavad palliatiivset ravi (raske haiguse sümptomite ravi, mis ei ole ette nähtud haiguse väljaravimiseks), manustatakse lisaks tavalistele lahtistitele Relistori nahaaluse süstega 1 kord ööpäevas iga 2 päeva järel.
English: It is not intended to provide practical advice on how to use Relistor.
Estonian: Hindamisaruandes ei anta Relistori kasutamise praktilisi nõuandeid.
English: By blocking these receptors, Relistor reduces the constipation due to opioids, but does not interfere with their painkilling effects.
Estonian: Neid retseptoreid blokeerides vähendab Relistor opioidide põhjustatud kõhukinnisust, kuid ei häiri nende valuvaigistavat toimet.
English: Relistor is used to treat constipation caused by opioid painkillers (such as morphine) when laxative medicines have not worked well enough.
Estonian: Relistori kasutatakse opioid-valuvaigistite (näiteks morfiini) põhjustatud kõhukinnisuse raviks, kui lahtistitest ei piisa.
English: Relistor contains the active substance methylnaltrexone bromide.
Estonian: Relistor sisaldab toimeainena metüülnaltreksoonbromiidi.
English: In patients not on palliative care, Relistor is given as an injection under the skin at a dose of 12 mg once a day, for at least 4 days per week and up to 7 days per week as needed; treatment with usual laxatives should be stopped when starting Relistor.
Estonian: Patsientidele, kes ei saa palliatiivset ravi, manustatakse Relistori nahaaluse 12 mg süstena üks kord ööpäevas 4-7 päeval nädalas; Relistori ravi alustamisel tuleb ravi tavaliste lahtistitega lõpetada.
English: Relistor must not be used in patients whose bowel is blocked, who are at risk of recurrent bowel blockage or who have a condition that needs immediate bowel surgery.
Estonian: Relistori ei tohi kasutada patsiendid, kellel on soolesulgus, korduva soolesulguse risk või kohest soolekirurgiat nõudev terviseseisund.
English: For more information about treatment with Relistor, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Relistoriga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Methylnaltrexone bromide is less able to enter the brain than naltrexone, meaning that it blocks the mu-opioid receptors in the gut but not in the brain.
Estonian: Metüülnaltreksoonbromiid levib ajju vähem kui naltreksoon, mistõttu blokeerib μ-opioidiretseptorid seedetraktis, kuid mitte ajus.
English: It is available as a solution for injection in vials or in prefilled syringes.
Estonian: Seda turustatakse süstelahusena viaalides või eeltäidetud süstaldes.
English: For practical information about using Relistor, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Relistori kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: Patients can inject Relistor themselves once they have been trained appropriately.
Estonian: Pärast asjakohase väljaõppe saamist tohivad patsiendid süstida endale Relistori ise.
English: Relistor was shown to be more effective than placebo (a dummy treatment) at stimulating bowel movement in two main studies involving a total of 288 patients with an advanced illness and constipation caused by opioids.
Estonian: Relistori võrreldi platseeboga (näiv ravim) kahes põhiuuringus, milles osales kokku 288 kaugelearenenud haiguse ja opioidide põhjustatud kõhukinnisusega patsienti.
English: The main measures of effectiveness were the number of patients who had a bowel movement within four hours of the first dose, and the percentage of injections that were successful in producing a bowel movement.
Estonian: Efektiivsuse põhinäitaja oli nende patsientide arv, kellel käis kõht läbi 4 tunni jooksul pärast esimest annust, ja selliste süstete protsent, mille tulemusena käis kõht läbi.
English: What are the risks associated with Relistor?
Estonian: Mis riskid Relistoriga kaasnevad?
English: Methylnaltrexone bromide is derived from naltrexone, a well-known substance that is used to block the action of opioids.
Estonian: Metüülnaltreksoonbromiid on saadud naltreksoonist, opioidide toime blokeerimiseks kasutatavast tuntud ainest.
English: For the full list of all side effects reported with Relistor, see the package leaflet.
Estonian: Relistori kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: Relistor is usually injected under the skin of the upper legs, belly or upper arms.
Estonian: Relistori süstitakse tavaliselt reie, kõhu või õlavarre naha alla.
English: When opioids attach to the gut receptors, the mobility of the gut is reduced, leading to constipation.
Estonian: Kui opioidid seonduvad seedetraktis olevate retseptoritega, väheneb soolemotoorika ja tekib kõhukinnisus.
English: How does Relistor work?
Estonian: Kuidas Relistor toimib?
English: Relistor methylnaltrexone bromide
Estonian: Relistor metüülnaltreksoonbromiid
English: The main measure of effectiveness in both studies was the number of patients who had a bowel movement within four hours of the first dose.
Estonian: Mõlemas uuringus oli efektiivsuse põhinäitaja nende patsientide arv, kellel 4 tunni jooksul pärast esimese annuse manustamist käis kõht läbi.
English: The second study also looked at the number of patients who had a bowel movement at least twice within four hours of the first four doses.
Estonian: Teises uuringus hinnati veel ka nende patsientide arvu, kellel 4 tunni jooksul pärast esimese 4 annuse manustamist käis kõht läbi vähemalt kaks korda.
English: How is Relistor used?
Estonian: Kuidas Relistori kasutatakse?
English: What benefits of Relistor have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Relistori kasulikkus?
English: Looking at the results of the two studies taken together, 55% of the patients receiving Relistor had a bowel movement within four hours of the first dose (91 out of 165), compared with 15% of the patients receiving placebo (18 out of 123).
Estonian: Mõlema uuringu kokkuvõttes oli patsiente, kellel käis 4 tunni jooksul pärast esimest süstet kõht läbi, Relistori kasutanute seas 55% (91 patsienti 165st) ja platseeborühmas 15% (18 patsienti 123st).
English: In the second study, 52% of the patients receiving Relistor had a bowel movement at least twice within four hours of the first four doses (32 out of 62), compared with 8% of those receiving placebo (6 out of 71).
Estonian: Teises uuringus oli patsiente, kellel käis 4 tunni jooksul pärast esimest 4 annust kõht vähemalt kaks korda läbi, Relistori kasutanute seas 52% (32 patsienti 62st) ja platseeborühmas 8% (6 patsienti 71st).
English: Opioids relieve pain by attaching to ‘opioid receptors' in the brain and spinal cord.
Estonian: Opioidid leevendavad valu aju ja seljaaju opioidiretseptoritega seondudes.
English: Results showed that 34% of patients receiving Relistor (102 out of 298) had a bowel movement within four hours after the first injection, compared with 10% of those receiving placebo (16 out of 162).
Estonian: Patsiente, kellel käis nelja tunni jooksul pärast esimest süsti kõht läbi, oli Relistori saanute seas 34% (102 patsienti 298st) ja platseeborühmas 10% (16 patsienti 162st).
English: Relistor can only be obtained with a prescription.
Estonian: Relistor on retseptiravim.
English: The active substance in Relistor, methylnaltrexone bromide, is a ‘mu-opioid receptor antagonist'.
Estonian: Relistori toimeaine metüülnaltreksoonbromiid on μ-opioidiretseptorite antagonist, mis blokeerib teatud tüüpi opioidiretseptorid (μ-opioidiretseptorid).
English: The dose of Relistor should be reduced in patients who have severe kidney problems.
Estonian: Raskete neeruprobleemidega patsientidel on vaja Relistori annust kohandada.
English: • Information on the identified and potential risks.
Estonian: • Informatsioon tuvastatud ja võimalike ohtude kohta.
English: The MAH shall agree the details of an educational programme with the National Competent Authorities and must implement such programme nationally to ensure that, prior to prescribing, all physicians are provided with a healthcare professional information pack containing the following:
Estonian: müügiloa hoidja kooskõlastab õppeprogrammi üksikasjad kohaliku pädeva riigiasutusega ja peab rakendama selliseid programme riiklikult tagamaks, et kõik arstid oleksid enne ravimi väljakirjutamist varustatud tervishoiutöötajatele mõeldud informatsioonipaketiga, mis koosneb järgnevast:
English: • Summary of Product Characteristics (SPC) and Package Leaflet and Labelling
Estonian: • Ravimi omaduste kokkuvõte (SPC) ja pakendi infoleht ning märgistus.
English: The Member States should ensure that all conditions or restrictions with regard to the safe and effective use of the medicinal product described below are implemented:
Estonian: Liikmesriigid peavad kindlustama, et kõik allpool kirjeldatud ravimi ohutu ja efektiivse kasutamisega seotud tingimused või piiragud oleksid rakendatud:
English: Key elements to be included in the educational material
Estonian: Õppematerjal peab sisaldama järgmisi võtmeelemente
English: • Information on gel depot formation and possible injections site reactions
Estonian: • Informatsioon geeli depoo moodustumise ja võimalike kõrvaltoimete kohta süstekohal
English: • Educational material
Estonian: • Õppematerjal
English: • Instructions for administration
Estonian: • Manustamisjuhendid
English: • Posology
Estonian: • Annustamine
English: The Reference Member States were Germany, Hungary, Norway, Poland, Slovakia, Spain, United Kingdom.
Estonian: Asjassepuutuvad liikmesriigid olid Saksamaa, Ungari, Norra, Poola, Slovakkia, Hispaania, Ühendkuningriik.
English: 1 Article 29(2) of Directive 2001/83/EC, as amended.
Estonian: 1 Direktiivi 2001/83/EÜ muudetud redaktsiooni artikli 29 lõige 2.
English: The final opinion was converted into a Decision by the European Commission on 11/10/2006.
Estonian: Lõplik arvamus muudeti Euroopa Komisjoni otsuseks 11/10/2006.
English: The Mutual Recognition Procedure started on 21 October 2005.
Estonian: Vastastikuse tunnustamise menetlust alustati 21. oktoobril 2005.
English: These Member States were not been able to reach an agreement in respect of the Mutual Recognition of the Marketing Authorisation granted by the Reference Member State.
Estonian: Kõnealused liikmesriigid ei suutnud jõuda kokkuleppele vastastikuse tunnustamise asjus, mille viiteliikmesriik müügiloale tagab.
English: The Denmark referred the reasons for disagreement to the EMEA on 31 March 2006.
Estonian: Taani esitas EMEAle lahkarvamuste põhjused 31. märtsil 2006.
English: A positive opinion was adopted 28 June 2006.
Estonian: Heakskiitev arvamus võeti vastu 28. juunil 2006.
English: The arbitration procedure started on 27 April 2006.
Estonian: Vahekohtu menetlust alustati 27. aprillil 2006.
English: The list of the product names concerned is given in Annex I. The scientific conclusions are provided in Annex II, together with the Summary of Product Characteristics in Annex III.
Estonian: Asjassepuutuvate raviminimetuste loetelu on I lisas, teaduslikud järeldused II lisas ja ravimi omaduste kokkuvõte III lisas.
English: Lekkerkerker (Netherlands) as Rapporteur and Dr. Hudson (United Kingdom) as Co-rapporteur.
Estonian: Inimtervishoius kasutatavate ravimite komitee määras ettekandjaks dr. J. F. F. Lekkerkerkeri (Madalmaad) ja kaasettekandjaks dr. Hudsoni (Ühendkuningriik).
English: Winthrop Pharmaceuticals UK Ltd submitted applications for mutual recognition of Doxazosin “Winthrop” 4 mg prolonged release tablets and associated names on the basis of the marketing authorisation granted by the Denmark on 30 September 2002.
Estonian: Ettevõte Winthrop Pharmaceuticals UK Ltd esitas Doxazosin Winthrop 4 mg toimeainet prolongeeritult vabastavate tablettide ja sarnaste nimetuste vastastikuse tunnustamise taotlused müügiloa alusel, mis oli väljastatud Taanile 30. septembril 2002.
English: During the June 2006 meeting, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, was of the opinion that the benefit/risk ratio is favourable for Doxazosin “Winthrop” 4 mg prolonged release tablets and associated names, that the objections raised should not prevent the granting of a Marketing Authorisation and that the Summary of Product Characteristics, labelling and package leaflet of the Reference Member State should be amended.
Estonian: Kõigi esitatud andmete põhjal ja komitees toimunud teadusliku arutelu käigus jõudis inimtervishoius kasutatavate ravimite komitee oma juunis 2006 peetud koosolekul arvamusele, et Doxazosin Winthrop 4 mg toimeainet prolongeeritult vabastavate tablettide ja sarnaste nimetuste kasu ja riski vahekord on soodne ning tõstatatud vastulaused ei tohiks takistada müügiloa andmist, samuti tuleks viiteliikmesriigil muuta ravimi omaduste kokkuvõtet, märgistust ja pakendi infolehte.
English: The scope of the referral was to agree whether Doxazosin “Winthrop” 4mg prolonged release tablets differ significantly with regards to the release profile from the originator product with potential for increased incidence of adverse events such as dizziness and hypotension, whether there were significant differences in performance of test batches in the single dose phase of studies 5208 and 1995 and whether the applicant has deviated from CHMP guidelines on the design of the bioequivalence studies, particularly in relation to the effect of food.
Estonian: Esildise eesmärgiks oli leppida kokku, kas Doxazosin Winthrop 4 mg toimeainet prolongeeritult vabastavad tabletid erinevad toimeaine vabastamise profiili poolest oluliselt originaalravimist, nii et see võiks suurendada selliste kõrvalnähtude sagedust nagu peapööritus ja hüpertensioon; kas ühe annuse uuringutes 5208 ja 1995 kasutatud partiide toimes oli märkimisväärseid erinevusi; ning kas taotleja on eiranud inimtervishoius kasutatavate ravimite komitee bioekvivalentsuse uuringute ülesehituse suuniseid, eelkõige koostoimes toiduga.
English: COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) OPINION FOLLOWING AN ARTICLE 29(2)1 REFERRAL FOR Doxazosin “Winthrop” 4 mg prolonged release tablets and associated names International Non-Proprietary Name (INN): Doxazosin
Estonian: INIMTERVISHOIUS KASUTATAVATE RAVIMITE KOMITEE ARVAMUS PÄRAST ARTIKLI 29 LÕIKE 21 JÄRGSET ESILDIST Doxazosin Winthrop 4 mg toimeainet prolongeeritult vabastavate tablettide ja sarnaste nimetuste kohta Rahvusvaheline mittekaubanduslik nimetus (INN): doksasosiin
English: Doxazosin “Winthrop” 4 mg prolonged release tablets and associated names (Doxazosin) is receptor alfa blocking agent used in the treatment of patients with essential hypertension and in the symptomatic treatment of patients with benign prostatic hyperplasia.
Estonian: Doxazosin Winthrop 4 mg toimeainet prolongeeritult vabastavad tabletid ja sarnased nimetused (doksasosiin) sisaldavad alfaretseptori blokaatorit, mida kasutatakse patsientide essentsiaalse hüpertensiooni raviks ja eesnäärme healoomulise suurenemise sümptomaatiliseks raviks.
English: Supplementary information was provided by the Marketing Authorisation Holder on 23 May 2006.
Estonian: Müügiloa hoidja esitas täiendava teabe 23. mail 2006 ning jagas suulisi selgitusi 27. juunil 2006.
English: The study should be based on an agreed protocol.
Estonian: Uuring peaks põhinema kokkulepitud protokollil.
English: - Allow the area to dry for 15 minutes.
Estonian: - Laske piirkonnal 15 minutit kuivada.
English: Date of first authorisation: 15 November 2012 Date of latest renewal: 13 July 2017
Estonian: Müügiloa esmase väljastamise kuupäev: 15. november 2012 Müügiloa viimase uuendamise kuupäev: 13. juuli 2017
English: 31 December
Estonian: 31. detsember
English: No overall differences in safety or efficacy were observed between younger and older patients.
Estonian: Üldisi erinevusi ohutuses ja efektiivsuses nooremate ja eakamate patsientide vahel ei täheldatud.
English: Patients were followed every 3 months for 12 months (see table 5).
Estonian: Patsiente jälgiti 12 kuu jooksul iga 3 kuu järel (vt tabelit 5).
English: Instructions for use: - Open a new tube each time you use this medicine.
Estonian: Kasutusjuhend - Avage uus tuub iga kord, kui te seda ravimit kasutate.
English: The tube is for single use only and should be discarded after use (see section 6.6).
Estonian: Tuub on ainult ühekordseks kasutamiseks ja tuleb pärast kasutamist ära visata (vt lõik 6.6).
English: to <1/1,000); very rare (<1/10,000) and not known (cannot be estimated from the available data).
Estonian: kuni < 1/1000); väga harv (< 1/10 000) ja teadmata (ei saa hinnata olemasolevate andmete alusel).
English: The level of efficacy varied between the individual anatomical locations.
Estonian: Efektiivsuse tase varieerus erinevate anatoomiliste asukohtade lõikes.
English: Tubes should be discarded after first opening.
Estonian: Tuubid tuleb pärast esmast avamist ära visata.
English: - Avoid sunlight as much as possible (including sunlamps and tanning beds).
Estonian: - Vältige päikesevalgust nii palju kui võimalik (sh päevituslambid ja solaariumid).
English: The final study report shall be submitted:
Estonian: Lõplikud uuringu tulemused tuleb esitada:
English: Long term efficacy
Estonian: Pikaajaline efektiivsus
English: 8 weeks after randomisation
Estonian: 8 nädalat pärast randomiseerimist
English: Actinic keratosis does not occur in children, and this medicine must not be used in children and adolescents under 18 years of age.
Estonian: Aktiinilist keratoosi lastel ei teki ja seda ravimit ei tohi kasutada lastel ja noorukitel vanuses kuni 18 aastat.
English: Clear colourless gel.
Estonian: Selge värvitu geel.
English: Other medicines and Picato
Estonian: Muud ravimid ja Picato
English: As a precautionary measure, it is preferable to avoid the use of Picato during pregnancy.
Estonian: Ettevaatusmeetmena on parem vältida Picato kasutamist raseduse ajal.
English: Long-term follow up
Estonian: Pikaajaline järelkontroll
English: Experience with more than one treatment course
Estonian: Kogemused rohkem kui ühe ravikuuriga
English: Othera aOther includes shoulder, back, leg.
Estonian: Muua a Muude hulka kuuluvad õlg, selg, säär.
English: Hypersensitivity (including angioedema)
Estonian: Ülitundlikkus (sealhulgas angioödeem)
English: Results demonstrated no systemic absorption.
Estonian: Tulemused näitasid, et süsteemset imendumist ei toimu.
English: Experience with treatment of a larger area
Estonian: Kogemused suurema ala ravimisega
English: Pharmacotherapeutic group: Antibiotics and chemotherapeutics for dermatological use, other chemotherapeutics, ATC code: D06BX02.
Estonian: Farmakoterapeutiline rühm: antibiootikumid ja kemoterapeutikumid dermatoloogiliseks kasutamiseks, muud kemoterapeutikumid, ATC-kood: D06BX02.
English: Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000
Estonian: väga sage (≥ 1/10); sage (≥ 1/100 kuni < 1/10); aeg-ajalt (≥ 1/1000 kuni < 1/100); harv (≥ 1/10 000
English: At 12 months, the complete clearance rates in these groups were 31% and 19% respectively.
Estonian: 12. kuul olid täieliku paranemise esinemissagedused neis rühmades vastavalt 31% ja 19%.
English: - Do not apply more gel than your doctor has advised.
Estonian: - Ärge kandke nahale rohkem ravimit, kui arst on soovitanud.
English: If you have previously used Picato or other similar medicines tell your doctor before starting the treatment.
Estonian: Kui te olete varem kasutanud Picatot või muid sarnaseid ravimeid, teavitage sellest oma arsti enne ravi alustamist.
English: Wash the area with soap and water.
Estonian: Peske piirkonda seebi ja veega.
English: - Do not swallow this medicine.
Estonian: - Ärge seda ravimit alla neelake.